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Abstract
Background: Histoplasmosis is a fungal infection highly endemic in the American continent. The disease can be
severe in immunocompromised subjects. In immunocompetent subjects the clinical manifestations are variable.
Aim of this work was to review the cases of acute histoplasmosis in immunocompetent travelers reported in
literature.
Methods: A systematic review of literature was conducted. Electronic search was performed in Pubmed and
LILACS. Two reviewers independently extracted data on demographic, clinical and radiological features, and
treatment. Cases were classified according to Wheat’s definitions.
Results: Seventy-one studies were included in the analysis, comprising a total of 814 patients. Twenty-one patients
diagnosed at the Centre of Tropical Diseases, Negrar (VR), Italy were also included. The most common travel
destination was Central America (168 people, 29.8%); the most common way of exposure to histoplasma was the
exploration of caves and/or contact with bat guano (349 people, 60.9%). The multivariate logistic regression model
showed association between the development of disseminated histoplasmosis (DH) and activities that involved the
exploration of caves and/or the contact with bats’ guano (adjusted OR: 34.20 95% CI: 5.29 to 220.93) or other
outdoor activities (adjusted OR: 4.61 95% CI: 1.09 to 19.56). No significant difference in the attack rate between
countries of destination was observed (p-value: 0.8906, Kruskal-Wallis test).
Conclusions: Histoplasmosis often causes no or mild symptoms in immunocompetent individuals, although a
severe syndrome may occur. The infection can mimic other diseases, and the epidemiological risk of exposure is an
important clue to raise the index of suspicion.
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Background
Histoplasmosis is a fungal infection acquired by inhal-
ation of Histoplasma capsulatum var. capsulatum
microconidia. This fungus is endemic in the American
continent (North, Central and South America). Cases
have also been described in Africa, Asia, and Europe [1].
Histoplasmosis is both a disease originating from soil
(infections often occur after human disruption of the soil
that aerosolizes the hyphae and conidia of the organism
originating from the earth enriched with birds’ excreta)
and a sapronosis (originating from bats) [2, 3]. With rare
exceptions, this fungus infects.
its host via the respiratory route: microconidia are
inhalated and deposited in the terminal bronchioles and
alveoli of the lung.
Clinical manifestations of histoplasmosis depend on the
size of the inoculum and the patient’s immunological sta-
tus/underlying conditions. Low level of exposure in the
healthy host typically leads to an asymptomatic infection,
while the acute syndrome usually follows a heavy inocu-
lum [4]. In the latter case, chest radiographs usually show
diffuse interstitial or reticulonodular infiltrates, sometimes
associated with hilar or mediastinal lymphadenopathy [4].
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Systemic symptoms include fever with possible respiratory
impairment, sweats, weight loss, headache and gastro-
intestinal complaints. A subacute pulmonary syndrome is
also possible in case of low inoculum [4]. The most fre-
quent symptoms are cough, fever, malaise and fatigue, typ-
ically occurring over weeks to months before seeking
medical advice [4]. Solitary lung nodules (histoplasmo-
mas) or multiple pulmonary nodules may develop, charac-
terized by indefinite persistence of foci of infection.
Calcification is usually found in the center of a histo-
plasmoma or in concentric rings and is generally diag-
nostic, although it may require years to develop and is
not always present.
Pulmonary nodules may slowly enlarge and even cavi-
tate [5]; moreover, they are usually identified as inciden-
tal findings on chest radiographs or CT scans, and
differential diagnosis includes sarcoidosis, tuberculosis
(TB) and malignancies [6–8]. Chronic pulmonary histo-
plasmosis can be observed in individuals with underlying
lung conditions, and it is defined as failure to clear H.
capsulatum infection [4].
Symptoms and signs include cough, low-grade fever,
night sweats and weight loss. Chest radiographs show
interstitial or consolidative infiltrates associated with
cavitation or fluid-filled emphysematous bullae [4]. This
kind of pulmonary syndrome doesn’t resolve spontan-
eously, leading to gradual progression and destruction of
lung parenchyma. Mediastinitis, broncholitiasis, pericar-
ditis and a rheumatologic syndromes have been de-
scribed, too. The disease is particularly relevant for
immunosuppressed subjects, who are at risk of develop-
ing the disseminated form, which is often fatal if not
promptly recognized [4].
On the other hand, the infection is usually mild and
self-limiting in immunocompetent people [4], although, ap-
parently in rare cases, the disease can progress to a severe
form with high morbidity even in those individuals [9–12].
Objectives
Aim of our work was to review the literature on acute
histoplasmosis in immunocompetent travelers, describ-
ing the main characteristics of the infection in this sub-
group of patients. Secondary objectives were to
investigate the characteristics associated to the develop-
ment of disseminated histoplasmosis in travelers, and to
estimate the attack rate in different areas of the world.
Methods
We conducted a systematic review of case reports and case
series available in literature. We analyzed the epidemio-
logical and clinical features, diagnostic work-up, treatment,
and outcome of cases of acute histoplasmosis in immuno-
competent patients, with history of recent travel (≤
3 months) in an endemic area.
Electronic search was conducted in PubMed and LI-
LACS on 31st December 2016, and all papers published
up to that date were included. We included full texts
written in English, Italian, French, German, Spanish,
Portuguese.
Additional cases were sought from the reference list of
included papers and of non-included reviews. Moreover,
grey literature was sought through contact with authors.
Two authors, SS and AA, independently screened the
list of papers generated from the electronic search, using
EndNote program, version 6, 2012 Thomson Reuters.
SS and AA extracted the data on the basis of inclusion/
exclusion criteria and case definitions (reported below),
and entered all information in a database created with
Microsoft Office Excel 2007. Data collected were: age, sex,
country of exposure, activities done in the country, attack
rate and development of disseminated disease. The
Excel data base is available as supplementary material
(Additional file 1).
In case of discrepancies in the process of inclusion of
papers/data extraction, a consensus was reached through
discussion or involvement of a third reviewer (FG).
Inclusion criteria
-Case reports or case series on acute histoplasmosis.
-Patients with history of travel in an endemic area (in-
cluding travels from an area of no/low endemicity to an
area of high endemicity within a country) ≤ 3 months be-
fore the onset of symptoms.
-Immunocompetence status.
Exclusion criteria
-Reviews of literature.
-Cases describing patients presenting with radiologic
findings compatible with histoplasmosis (i.e. pulmonary
nodules) but no apparent temporal relationship with travel.
-Cases native from an endemic area without history of
travel to an area with higher endemicity.
-Non-immunocompetence status at the time of the
travel, at the onset of symptoms or at the time of diag-
nosis of histoplasmosis.
-Occupational exposure in native area.
-Cases of reactivation of histoplasmosis acquired in
the past.
-Cases of histoplasmosis due to Histoplasma capsula-
tum var. duboisii.
Case definition (adapted from wheat [13] and EORTC/MSG
criteria [14])
Proven
Illness consistent with acute histoplasmosis in a patient
who had recently (≤ 3 months) travelled to an endemic
area and one of the following:
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-Positive culture from a specimen obtained from the
affected site or tissue.
-Histopathologic or direct microscopic demonstration
of yeast intracellular forms or yeasts in tissue
macrophages.
Probable
-Host factor: recent travel (≤ 3 months) in area endemic
for histoplasmosis.
-Clinical picture and/or radiological findings consist-
ent with acute histoplasmosis.
-Mycological evidence (histoplasmin test positivity
and/or positivity of serology and/or positivity of
urine-serum Histoplasma antigen).
Possible
-Host factor: recent travel (≤ 3 months) in area endemic
for histoplasmosis.
-Clinical picture and/or radiological findings consist-
ent with acute histoplasmosis.
-No mycological evidence nor serologic evidence but:
Belonging to a histoplasmosis cluster and/or efficacy
of oral ex juvantibus itraconazole therapy (resolution of
symptoms and normalization of radiological findings).
Activities at risk for developing histoplasmosis
Contact with bats excreta and/or visit to a cave.
Outdoor activities: forest excursions/trekking, camping
or other activities not involving visit to caves or direct
contact with bats’ excreta.
Activities involving contact with chickens or other
non-mammal birds.
All activities that put the subject at risk of inhalating
Histoplasma microconidia: building construction, reno-
vation, excavation (biologists, building contractors, con-
struction workers, soldiers, volunteers involved in
churches or other buildings renovation).
Syndromic classification (according to wheat [13])
Asymptomatic (As): asymptomatic case identified through
laboratory screening within a histoplasmosis cluster.
Acute pulmonary histoplasmosis (AP): febrile illness
with respiratory symptoms and/or mediastinal involve-
ment and/or accompanying constitutional symptoms
and/or gastrointestinal or cutaneous involvement when
they are not the main manifestation.
Rheumathologic (R): a case with arthralgia or arthritis
as unique symptom.
Disseminated Histoplasmosis (DH): febrile illness with
demonstration of bone marrow involvement (leucopenia,
thrombocytopenia, anemia) AND/OR disseminated
monocytic-macrophage involvement (hepatosplenomegaly
AND/OR increased liver enzymes), with or without respira-
tory symptoms.
Statistical analysis
Descriptive statistics were used to analyze the character-
istics of the entire cohort. Categorical variables were re-
ported as frequencies and proportions, while
quantitative variables were presented as median (inter-
quartile range, IQR). Associations between covariates
were explored through univariate logistic models and
non-parametric Kruskal-Wallis rank sum test. Lastly, we
fitted a multivariate logistic regression model to assess
the impact of all covariates on the probability of con-
tracting the disseminated disease. All statistical analyses
were conducted using R, version 3.3.3 [15].
Results
The study selection process (PRISMA flow chart) is
shown in Fig. 1. The studies included in the analysis
through electronic search were 71 [8, 16–85], (Table
1) comprising a total of 814 patients (see Fig. 2 for the
timeline distribution of studies and cases respectively). In
the analysis were also included 21 patients diagnosed at the
Centre of Tropical Diseases (CTD) of Negrar, Verona, Italy
during the decade 2005–2015 (Staffolani S, Buonfrate D,
Farina C, Gulletta M, Gobbi F, Angheben A, manuscript in
preparation), for a total of 835 patients. Figure 3 shows the
countries of presumable exposure to the infection.
Regarding the cases diagnosed at the Centre of Trop-
ical Diseases, Negrar (VR), briefly, we found 21 cases of
acute histoplasmosis in immunocompetent subjects, 17
of them affecting members of a scientific expedition to
Ecuador. The other 4 patients did not belong to a cluster
and traveled to Panama, Bolivia, Mexico, Cuba respect-
ively. Seventeen out of 21 patients were male (81%). The
mean age was 38.5 years for the Ecuador cluster,
46.7 years for the other cases. They were infected
through contact with bat excreta, inhalation of contami-
nated soil, outdoor activities. All cases were classified as
possible histoplasmosis, but two probable for positive
serology and two proven cases based on histology. The
main symptoms were fever (12/21, 57%), respiratory (12/
21, 57%) and gastrointestinal (9/21, 43%) symptoms.
Seven patients (33%) were admitted to the hospital and
four of them underwent invasive diagnostic procedures
(bronchoscopy, biopsy of other tissues). Eleven out of 17
(65%) patients of the Ecuador cluster and 4/4 (100%) pa-
tients not belonging to it had abnormal blood exams.
Eleven patients (65%, 7/17 (41%) in the cluster and 4/4
(100%) not belonging to the Ecuador cluster) received
oral itraconazole. Nine patients (39.1%) had persistent
lung nodules at the 12-month radiological follow up.
Regarding all selected cases of the present review,
most patients (488/835, 59%) belonged to a cluster.
There were 45 clusters described by 36 authors, plus 2
clusters diagnosed at CTD. The cluster comprising the
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largest number of individuals (n= 262) was described by
Morgan [35].
While we considered all 835 patients for the descrip-
tion of main characteristics of cases, the “Acapulco clus-
ter” [35] was removed from our dataset for univariate
and multivariate analyses, as it did not contain informa-
tion regarding age or the state of disseminated disease.
Table 2 displays a summary of the characteristics of the
cohort of the 573 immunocompetent travelers consid-
ered for univariate and multivariate analyses.
Clinical-syndromic classification
According to the above-mentioned definitions, we found 32
proven, 695 probable and 108 possible histoplasmosis cases.
Most patients (605/724, 84%) had acute pulmonary
histoplasmosis (AP). Of them, 111 (18%) had also rheu-
matologic manifestations and 26 (4%) mediastinal
involvement. In this group we also included patients
with miliary pulmonary lesions if they had only re-
spiratory symptoms with no signs of dissemination.
Fifty-six (8%) cases were classified as Disseminated
Histoplasmosis (DH), 65 (9%) patients were asymp-
tomatic (A), 9 (1%) patients had only rheumatologic
(R) manifestations.
Symptoms
This information was available for 789/835 (94.5%) sub-
jects, of whom 724 reported symptoms. As it is shown
in Fig.4, the most frequent symptoms were fever (659/
724, 91%), cough (398, 55%), headache (377, 52%) and
chest pain (299, 41%). Constitutional symptoms (myalgia
and/or sweats, and/or weight loss, and/or anorexia) were
reported by 418 (58%) patients. Patients reporting chills,
with or without documented fever, were 91 (13%).
Fig. 1 PRISMA flow chart for study selection
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Table 1 Studies selected for the systematic review
Reference Publication
year
N°
cases
Country of
origin
Visited
continent
Visited country Reason
of travel
Exposure Cluster Syndromic
classification
Therapy Type of
therapy
1 [8] 2015 1 Swiss SA Brazil, Argentina C no AP yes itra
2 [16] 1988 15 NS CA Costa rica ST B yes AP no
3 [17] 2007 4 Spain SA Ecuador V C, S yes AP no
4 [18] 2004 1 France SA Colombia T B no AP yes NS
5 [19] 2011 2 Italy SA Ecuador O no AP, DH 1 yes Itra
6 [20] 1992 1 Germany SA Ecuador T O no AP no
7 [21] 2013 1 Israel SA, A Jordan, Bolivia, Brazil,
Ethiopia, Angola
T O no DH yes Itra
8 [22] 1995 2 France SA Guyana P O, S no AP yes Excision
9 [23] 2011 5 Spain A, SA, CA Angola, Venezuela,
Nicaragua, Ecuador
T, P, SP,
V
B, O no AP no
10 [24] 2002 14 Canada CA Belize ST O yes AP 1 yes itra
11 [25] 2013 1 USA SA Peru V B, S no DH yes AmB, itra
12 [26] 1999 1 France SA Guyana P O, S no DH yes itra
13 [27] 2013 12 Europe,
Africa
A Uganda ST O yes AP 5 yes 4 itra, 1
keto
.14 [28] 1979 10 A South Africa SP B yes 9 AP, 1 DH 1 yes AmB
15 [29] 1997 1 France SA Guyana P O, S no AP yes Itra
16 [30] 2006 1 Netherland A Ghana T B, O no AP no
17 [31] 1957 2 South
africa
A South Africa SP B yes AP no
18 [32] 2012 1 Germany SA Costa Rica T B, O no AP yes itra
19 [33] 2002 6 Germany CA Cuba BIO B, S yes 3 AP, 3 DH yes itra
20 [34] 2010 3 Japan Malaysia T O yes AP no
21 [35] 2003 262 USA Mexico T O, S yes AP yes NK
22 [36] 2000 4 Italy CA, SA Guatemala,
Dominican republic,
Peru
T, SP B, O, S no 3 AP, 1 DH yes 2keto, 1
itra, 1 amB
23 [37] 2005 1 Italy CA Nicaragua P O, S no AP yes itra
24 [38] 2003 3 Spain CA Nicaragua T B, O yes AP 1 yes itra
25 [39] 1988 11 USA USA Iowa T O, S yes AP no
26 [40] 2005 9 Spain SA Guatemala V S yes AP no
27 [41] 2000 7 Spain CA, SA Dominican Republic,
Nicaragua, Colombia,
Peru, Guatemala
T, V B, O, S no 1 AP, 8 DH yes itra
28 [42] 1962 3 Europe A South Africa SP B yes DH yes AmB
29 [43] 1990 1 France SA Guyana T O no AP no
30 [44] 1981 69 USA NA South Carolina CI C yes AP no
31 [45] 1975 6 Canada CA Puerto Rico ST, TEA B, O yes AP no
32 [46] 1979 1 Jamaica CA Caribbean TEA B no AP no
33 [47] 1996 1 Germany CA T O no AP no
34 [48] 2008 3 Austria Mexico T B no DH yes itra
35 [49] 2008 3 Germany CA Antille BIO B, S yes 2 DH, 1 AP yes itra
36 [50] 2012 4 Poland SA Ecuador T B yes DH 2 yes keto
37 [51] 2011 2 France CA Costa Rica T O yes AP 1 yes 1 itra
38 [52] 2003 1 Germany Mexico, Brazil T O no AP no
39 [53] 1979 27 USA USA North-Centre Florida V B, O, S yes 8 As, 2 DH
17 AP
2 yes 2 AmB
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Table 1 Studies selected for the systematic review (Continued)
Reference Publication
year
N°
cases
Country of
origin
Visited
continent
Visited country Reason
of travel
Exposure Cluster Syndromic
classification
Therapy Type of
therapy
40 [54] 2004 10 USA CA Costa Rica T B yes AP no
41 [55] 2013 1 Canada CA Costa Rica B, O, S no DH yes AmB, itra
42 [56] 2005 2 France SA Venezuela P O, S no AP yes itra
43 [57] 1991 1 France SA Guatemala T O, S no AP yes keto
44 [58] 2014 1 Germany SA Ecuador T O no AP yes itra
45 [59] 1957 64 Europe, NS A South Africa ST, SP B yes AP, 5 As no
46 [60] 1997 4 Italy SA Peru SP B, C yes DH yes keto
47 [61] 1995 24 Europe,
SEA
AU New Caledonia SP B yes AP, 3 As 21 yes Keto, itra,
AmB
48 [62] 2009 5 Spain CA, SA Peru, Costa Rica, El
Salvador, Panama,
Ecuador
T, BIO, V,
P
B, C, O, S no 3 AP, 2 DH Yes 1
pulmonary
and 2 DH
itra
49 [63] 2001 1 Spain SA Peru T B, O no AP yes itra
50 [64] 2014 4 Brazil SA Brazil BIO B yes AP 2 yes itra
51 [65] 1986 6 USA USA Florida ST, P B, S yes AP 4 yes 2Amb,2keto
52 [66] 2006 1 USA CA Guatemala T O no R yes itra
53 [67] 2003 13 France CA Martinica Trekking
trip
O, S yes 11 DH, 2 AP yes itra
54 [68] 2009 1 Germany CA Antille BIO B, S no AP yes NS
55 [69] 2015 23 Israel USA, CA,
SA
Guatemala, Costa
Rica Peru, Mexico,
Bolivia, Indiana,
Dominican Republic
NS B, O no 14 AP, 9 As Not known
56 [70] 2011 3 France CA Cuba SP B yes 1 DH, 2 AP yes itra
57 [71] 2007 1 Japan SA Bolivia P O, S no AP yes fluco
58 [72] 1992 1 Italy A P O, S no AP yes AmB
59 [73] 2000 12 Spain CA, SA Guatemala,
Honduras, Nicaragua,
Dominican Republic,
Peru
V, SP, T B, O, S yes 7 AP, 5 As 8 yes itra
60 [74] 1999 11 USA SA Ecuador ST B yes 1 DH, 8 AP,
2 not
possible
4 yes 1 itra, 3
systemic
azoles
61 [75] 2008 20 USA CA El Salvador V O, S yes AP Not known
62 [76] 2003 14 USA CA Nicaragua ST B yes 4 DH, 8 AP,
2 As
yes itra
63 [77] 1999 6 Chile SA Ecuador T C, O yes AP yes itra
64 [78] 1966 2 USA USA Missouri, Kentucky T C no AP 1 yes AmB
65 [79] 2015 1 USA USA Southwest T O, S no AP yes itra
66 [80] 2010 4 Brasil SA Brasil SP B yes 2 AP, 2 DH yes
67 [81] 2012 5 Argentina SA Argentina O C Yes AP No
68 [82] 2002 1 Chile SA Peru SP B No AP Yes
69 [83] 2001 31 Venezuela SA Venezuela SP B Yes AP No
70 [84] 1981 33 colombia SA colombia SP B yes AP no
71 [85] 1999 1 Taiwan SEA Indonesia P O no DH yes AmB
CTD
Negrar
2016 21 Italy SA, CA Ecuador, Bolivia,
Mexico, Cuba
T, SP, P B, O, S 16 yes,
5 no
1 DH, 20 AP 11 yes itra
NS not specified, USA United States of America, NA North America, CA Central America, SA South America, A Africa, AU Australia, SEA South East Asia, ST
student, V Volunteer, T Tourist, P professional, SP Speleologist, BIO Biologist, CI Correctional Institute TEA Teacher, B Cave_bats, C Birds/chickens, S
Moved Soil, O Outdoor activities, DH Disseminated Histoplasmosis, AP Acute Pulmonary Histoplasmosis, AmB Amphotericin B, Itra Itraconazole, Fluco
Fluconazole, Keto Ketoconazole
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Gastrointestinal symptoms (158/724, 22%) comprised
diarrhea, nausea, abdominal pain or vomit. Oral lesions
(5/724, 0.7%) were aftous in 3 cases, ulcerative (lingual
and tonsillar), and papular (lingual) in one patient each.
Skin abnormalities (41/724, 5.5%) were: diffuse macular
rash in 32/41 (78%) patients, erythema nodosum in 5
(12%), while cutaneous ulcers, papules, and splinter
hemorrhages were reported in one case each. For a fur-
ther patient the type of cutaneous lesion was not speci-
fied. Symptoms attributed to central nervous system
impairment (14/724, 2%) included irritability, insomnia,
dizziness, lethargy.
Ophtalmological symptoms (7/724, 1%) were conjunc-
tivitis, ocular pain, photofobia.
Laboratory exams
This information was available for 212 (25%) patients.
Of them, 90 (42%) had abnormal laboratory exams (ab-
normal leucocyte and/or platelet count or anemia, in-
creased inflammatory markers, increased LDH,
abnormal liver enzymes values). In particular: 27 (30%)
had abnormal leucocyte and/or platelet count or anemia,
62 (69%) had increased inflammatory markers, 26 (29%)
had increased LDH, 45 (50%) had abnormal liver en-
zymes values.
Information about Histoplasma serology was available
for 634 (76%) patients, of whom 413 (65%) were positive.
All asymptomatic patients included in the analysis were
positive to serology, which was performed on the basis
of epidemiological suspicion (travel with patients diag-
nosed with histoplasmosis). Of 213 (26%) patients
screened with histoplasmin skin test, 199 (93%) resulted
positive.
Imaging
Imaging included chest X ray and CT scan. This infor-
mation was available for 376 (45%) patients. Of them,
250 (67%) showed abnormal imaging. In particular:
nodular infiltrates were present in 200 patients (80%),
patches in 16 patients (6%), miliary pattern in 14 pa-
tients (6%), hylar/mediastinal adenopathies in 49 pa-
tients (20%), pleural effusion in 4 patients (2%).
Fig. 2 Timeline distribution of the studies reporting cases of acute histoplasmosis in immunocompetent travelers. Each bubble corresponds to a
study, the diameter of the bubble is proportional to the number of cases described in the study, which correspond to the projection of the
center of the bubble on the ordinate axis
Staffolani et al. BMC Infectious Diseases          (2018) 18:673 Page 7 of 14
Information about the spleen and liver size was available
only for 14 (2%) patients, of whom 5 (36%) had hepatos-
plenomegaly and one had hepatomegaly.
Hospitalization and invasive procedures
Information about hospitalization was available for
595 (71%) patients, of whom 130 (22%) were admitted
to hospital. Information about diagnostic procedures
was available for 742 patients (89%). Of them, 64 pa-
tients (9%) underwent invasive procedures. Usually,
obtained specimens were sent for coltural, cytologic
and/or histological examination. Fiftyseven out of 62
patients (92%) had a positive colture for Histoplasma,
9/61 (15%) had positive cytologic examination (7 of
them had a positive hystologic exam, too), 37/63
(59%) had positive pathology findings (of them 21 had
also positive colture and 4 had also a positive cytologic
examination).
Fourtyfive patients (70%) underwent bronchoscopy
with bronchoalveolar lavage (BAL), and 21 (47%) of
them underwent lymphonodal biopsy, too. Of all them,
26/44 (59%) had positive mycologic colture, 8/44 (18%)
had positive cytologic exam and 20/45 (44%) had posi-
tive histologic exam. Eighteen patients had more than
one positive result.
Thirteen patients (20%) were submitted to transtho-
racic lung biopsy. Seven out of 13 (54%) coltural exams,
1/13 (8%) cytologic exams and 9/13 (69%) histological
exams were positive. Four patients had more than one
positive exam.
Eight patients (13%) underwent lung resection. Two
out of 8 (25%) coltural and 7/7 (100%) histological ex-
aminations were positive.
Finally, six patients (9%) underwent biopsies of tissues
other than lung (bone marrow 5 patients, skin one pa-
tient). Five out of 6 (83%) coltural exams and 5/6 (83%)
histological exams were positive. Four patients had both
coltural and histological positive exams.
Treatment
Information was available for 744 patients (89%). Of
them, 185 (25%) received antifungal therapy. In par-
ticular: 105 (57%) patients received oral itraconazole,
while 21 (11%) received intravenous amphotericin B.
Twelve (57%) of the latter were switched to oral
drugs at hospital discharge: one of them was
switched initially to oral itraconazole and then to
posaconazole, 8 of them were switched to ketocona-
zole and then to itraconazole, 4 were switched to
itraconazole. Twenty-four (13%) patients were
Fig. 3 Distribution of acute histoplasmosis reported cases among immunocompetent travelers
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treated with systemic azoles other than itraconazole,
while 33 (18%) patients were treated with an un-
specified antifungal therapy. A couple of patients
with lung nodules underwent excisional surgery and
no antifungal therapy.
Outcome
A detailed information about the outcome was avail-
able for 727 (87%) patients. Most of them (726/727,
99.8%) recovered. In particular: 688 (95%) patients
had complete clinical and radiological resolution at
the last visit, while 38 (5%) patients had clinical re-
covery and a partial clearance of the radiological find-
ings. One patient with disseminated histoplasmosis
and typhoid fever died because of multi-organ failure
and hypercalcemia [85].
Univariate and multivariate analyses
Table 3 reports a summary of the univariate and multi-
variate analyses conducted on all variables of interest.
Results from the univariate analysis showed an associ-
ation between disseminated histoplasmosis and variables
such as age (crude OR: 1.03 95% CI: 1.01 to 1.05), Cen-
tral America (crude OR: 13.01 95% CI: 3.82 to 81.43) or
South America (Crude OR: 6.66 95% CI: 1.84 to 42.72)
as a destination, and activities that involved inhalation of
contaminated soil (crude OR: 3.13 95% CI: 1.72 to 5.62).
However, the multivariate logistic regression model did
not confirm any association with destination or age,
while a strong association was found with activities that
involved the exploration of a cave full of bat’s guano (ad-
justed OR: 34.20 95% CI: 5.29 to 220.93) or other out-
door activities (adjusted OR: 4.61 95% CI: 1.09 to 19.56).
No significant difference in the attack rate between
countries of destination was observed (p-value: 0.8906,
Kruskal-Wallis test. Not reported in tables).
Discussion
We were able to identify in the literature 814 cases of
histoplasmosis acquired by immunocompetent travelers,
for a total of 835 patients including those diagnosed at
CTD. Considering that this occurrence is certainly
under-diagnosed and under-reported, we assume that
the published cases must be the tip of the iceberg. We
hope that our systematic review may contribute to raise
awareness of the possible occurrence of this condition in
travelers visiting endemic countries/areas. It is true that
most cases are clinically not severe, nevertheless most of
the subjects presented symptoms of various degree,
moreover usually long lasting, often implying otherwise
unnecessary, invasive diagnostic procedures under the
suspicion of more common (and serious) causes such as
TB or lung malignancies. Only less than 10% of the sub-
jects were apparently asymptomatic, although it should
be recognized the low probability of a pauci- or
asymptomatic case to be identified and described in
the literature. Of particular note, a relatively large
group of patients had Disseminated Histoplasmosis
(DH), confirming that this condition, although typical
of immunosuppressed individuals, may also occur in
immunocompetent subjects. Moreover, given the long
course of the infection, an unrecognized/untreated
case of histoplasmosis may reactivate later in life,
under immune suppressant conditions. Are there any
definite risk factors for DH in immunocompetent in-
dividuals? We found several associations between dis-
seminated histoplasmosis and other covariates at
univariate analysis (Table 2). However, these results
appear to be very inconsistent and were not con-
firmed by multivariate analysis and therefore no con-
clusion can be drawn from them. At multivariate
analysis, the only risk factors resulting significant
were exposition to cave-bats and outdoor activities.
We found no association between the attack rate and
the different endemic areas, hence we cannot suppose that
there is a difference in the aggressiveness of the different
strains throughout the world. In contrast with this conclu-
sion, some authors [86–90] supposed that different and
Table 2 Baseline Demographic and Travel Characteristics of the
Entire Cohort of Immunocompetent Travelers
Characteristic Entire Cohort
N, %
Total 573
Median age, years (IQR) 29 (23–43)
Male, N (%) 244 (64.0)
Median AR a, % (IQR) 90 (73.2–100.0)
Continent of destination, N (%)
USA-Canada 117 (20.8)
Central America 168 (29.8)
South America 154 (27.4)
Africa 95 (16.9)
Others b 29 (5.1)
Activity c, N (%)
Caves/Bat guano 349 (60.9)
Outdoor activities 198 (34.5)
Bird_chickens 105 (18.3)
Inhalation_soil 104 (18.1)
Abbreviations, AR attack rate, IQR interquartile range
a Calculated as the proportion of infected people in the travel group. We
identified 47 travel groups in the cohort
b Includes: Asia, Oceania
c Frequencies exceed 100%, as most people did more than one activity during
the trip. Caves/Bat’s guano: contact with bats excreta and/or visit to a cave.
Outdoor activities: forest excursions/trekking, camping or other activities not
involving visit to caves or direct contact with bats’ excreta. Bird_chickens:
activities involving contact with chickens or other non-mammal birds.
Inhalation_soil: all activities involving building construction, renovation,
excavation (biologists, building contractors, construction workers, soldiers,
volunteers involved in churches or other buildings renovation)
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specific Histoplasma capsulatum genotypes could be re-
sponsible of the variability of clinical manifestations, in
particular some “aggressive” strains might cause a more
severe presentation. It is to be mentioned that our result
is based on 47 groups only, and the observation of more
groups in endemic areas would possibly provide a more
robust conclusion. Seventy-eight per cent of reported
cases acquired the infection in the American continent,
and 57,2% in Central-South America only; these areas
should be therefore considered “highly” endemic, although
the disease can be seen globally.
From the clinical point of view, when should histoplas-
mosis be suspected in a returning traveler? Histoplasmosis
can be misdiagnosed, not only because of the common low
awareness of health-care workers but especially because
the clinical picture is mainly characterized by fever (more
than 90% of reported cases) associated to respiratory symp-
toms in around half of cases. More than 80% of patients
have a pulmonary form. Therefore, histoplasmosis should
be suspected in all travelers presenting with fever/systemic
symptoms or community-acquired pneumonia. History
should be carefully evaluated, in particular exposure to
cave/bats or simply outdoor activities in endemic areas
(particularly the American continent) and being part of a
cluster of similar illness. Although the most part of cases
in our review had also abnormal laboratory exams (two
thirds of cases had increased inflammatory markers and
half increased transaminases) this is an aspecific finding,
especially in pneumonia/febrile systemic illness. However,
Histoplasma serology is positive in two third of cases. Ac-
cording to Wheat [4], Histoplasma galactomannan antigen
can be positive in 80–95% of cases in the acute pulmonary
and disseminated form and could strongly contribute to
diagnosis when available.
Finally, radiologic findings can be of help to distin-
guish histoplasmosis from bacterial/viral pneumonia in
immunocompetent travelers; in our review, 80% of re-
trieved cases with this information showed pulmonary
nodules (typically multiple peripheric nodules with halo
sign at computed tomography). Our study has some lim-
itations. First, we excluded some papers by language, in
particular those written in Chinese and Dutch, and this
could have led to the loss of some cases. We did not find
a standardized definition of acute histoplasmosis in the
immunocompetent subject in the scientific literature,
hence we adapted the definition and the inclusion
Fig. 4 Frequency of symptoms reported
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criteria on the basis of the works of prominent authors,
namely Wheat and EORTC/MSG experts [4] [13, 14].
Most of all, it was difficult to retrieve accurate information
about the outcome, that was not always described in details.
However, with the limitation of a various and not ever re-
ported follow-up, more than 99% of subjects recovered or
had a consistent clinical and radiological improvement.
Inconsistency in the analysis of risk factors for Dissem-
inated Histoplasmosis is most probably due to the low
quality of the gathered data, that is probably explained
by the vast heterogeneity of the sources across the years
of publication and the differences in the statistics re-
ported. We tried to implement different logistic models
to verify which one could have a better goodness of fit,
but unsuccessfully. We also tried data imputation to im-
prove the completeness of the dataset. Namely, we tried
to complete data on age and sex through a Multivariate
Imputation by Chained Equations (MICE) [88] with
the predictive mean matching method, in order to
maintain the original distribution of age and sex of
the incomplete data. Unfortunately, this did not have
an impact on the quality of results. However, the ex-
posure to cave-bats and outdoor activities resulted
significant in the majority of models we fitted, so we
assume that there is an association with those vari-
ables. We finally decided to report results from the
best model in terms of goodness of fit.
Conclusions
Presumably, cases of histoplasmosis in immunocompetent
travelers are largely misdiagnosed and under-reported, be-
cause these subjects are usually asymptomatic or present
mild symptoms. However, it is important to consider this
infection in the differential diagnosis in case of epidemio-
logical risk of exposure, also in light of possible (though
rare) progression of the disease also in immunocompetent
individuals. In addition, the risk of reactivation of the infec-
tion in case of subsequent acquired immunosuppression is
present, even after a long time [91]. Studies are needed to
understand whether antifungal therapy prescribed for the
acute, mild form of the disease could prevent further reacti-
vations. Finally, a high index of suspicion might avoid un-
necessary hospitalization and invasive procedures.
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